Literature DB >> 21956511

Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories.

Zoe Moodie1, Leah Price, Sylvia Janetzki, Cedrik M Britten.   

Abstract

ELISPOT assay readout is often dichomized as positive or negative responses according to prespecified criteria. However, these criteria can vary widely across institutions. The adoption of a common response criterion is a key step toward cross-laboratory comparability. This chapter describes the two main approaches to response determination, identifying the strengths and limitations of each. Nonparametric statistical tests and consideration of data quality are recommended and instructions provided for their ready implementation by nonstatisticians and statisticians alike.

Mesh:

Year:  2012        PMID: 21956511     DOI: 10.1007/978-1-61779-325-7_15

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  22 in total

1.  Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial.

Authors:  Nicolai Grønne Jørgensen; Shamaila Munir Ahmad; Niels Abildgaard; Per Thor Straten; Inge Marie Svane; Mads Hald Andersen; Lene Meldgaard Knudsen
Journal:  Stem Cell Investig       Date:  2016-12-23

2.  The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.

Authors:  Shamaila Munir Ahmad; Evelina Martinenaite; Morten Holmström; Mia Aaboe Jørgensen; Özcan Met; Claudia Nastasi; Uffe Klausen; Marco Donia; Lars Møller Pedersen; Lars Munksgaard; Niels Ødum; Anders Woetmann; Inge Marie Svane; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2017-11-01       Impact factor: 8.110

3.  Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer.

Authors:  Mads Duus Hjortsø; Stine Kiaer Larsen; Per Kongsted; Özcan Met; Thomas Mørch Frøsig; Gitte Holmen Andersen; Shamaila Munir Ahmad; Inge Marie Svane; Jürgen C Becker; Per Thor Straten; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2015-01-30       Impact factor: 8.110

4.  T-cell Responses to HSV-1 in Persons Who Have Survived Childhood Herpes Simplex Encephalitis.

Authors:  Mariliis Ott; Lichen Jing; Lazaro Lorenzo; Jean-Laurent Casanova; Shen-Ying Zhang; David M Koelle
Journal:  Pediatr Infect Dis J       Date:  2017-08       Impact factor: 2.129

5.  Spontaneous presence of FOXO3-specific T cells in cancer patients.

Authors:  Stine Kiaer Larsen; Shamaila Munir Ahmad; Manja Idorn; Özcan Met; Evelina Martinenaite; Inge Marie Svane; Per Thor Straten; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2014-11-14       Impact factor: 8.110

6.  Frequent adaptive immune responses against arginase-1.

Authors:  Evelina Martinenaite; Rasmus Erik Johansson Mortensen; Morten Hansen; Morten Orebo Holmström; Shamaila Munir Ahmad; Nicolai Grønne Dahlager Jørgensen; Özcan Met; Marco Donia; Inge Marie Svane; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2017-12-26       Impact factor: 8.110

7.  Cellular Interferon Gamma and Granzyme B Responses to Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in Elderly.

Authors:  Heidi Theeten; Catharina Mathei; Kelly Peeters; Benson Ogunjimi; Herman Goossens; Margareta Ieven; Pierre Van Damme; Nathalie Cools
Journal:  Viral Immunol       Date:  2016-03-22       Impact factor: 2.257

8.  Interleukin-12p70 expression by dendritic cells of HIV-1-infected patients fails to stimulate gag-specific immune responses.

Authors:  Ellen Van Gulck; Nathalie Cools; Derek Atkinson; Lotte Bracke; Katleen Vereecken; Marc Vekemans; Viggo F I Van Tendeloo; Zwi N Berneman; Guido Vanham
Journal:  Clin Dev Immunol       Date:  2012-07-12

9.  Defining ELISpot cut-offs from unreplicated test and control wells.

Authors:  Neal Alexander; Annette Fox; Vu Thi Kim Lien; Tao Dong; Laurel Yong-Hwa Lee; Nguyen Le Khanh Hang; Le Quynh Mai; Peter Horby
Journal:  J Immunol Methods       Date:  2013-03-07       Impact factor: 2.303

10.  The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells.

Authors:  Shamaila Munir; Gitte Holmen Andersen; Inge Marie Svane; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.